Cargando…
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982393/ https://www.ncbi.nlm.nih.gov/pubmed/31980023 http://dx.doi.org/10.1186/s12943-020-1141-9 |
_version_ | 1783491303919583232 |
---|---|
author | Zhong, Xiaoming Zhang, Hangtian Zhu, Ying Liang, Yuqing Yuan, Zhuolin Li, Jiachen Li, Jing Li, Xin Jia, Yifan He, Tian Zhu, Jiangyuan Sun, Yu Jiang, Wengting Zhang, Hui Wang, Cheng Ke, Zunfu |
author_facet | Zhong, Xiaoming Zhang, Hangtian Zhu, Ying Liang, Yuqing Yuan, Zhuolin Li, Jiachen Li, Jing Li, Xin Jia, Yifan He, Tian Zhu, Jiangyuan Sun, Yu Jiang, Wengting Zhang, Hui Wang, Cheng Ke, Zunfu |
author_sort | Zhong, Xiaoming |
collection | PubMed |
description | Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs. |
format | Online Article Text |
id | pubmed-6982393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69823932020-01-29 Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy Zhong, Xiaoming Zhang, Hangtian Zhu, Ying Liang, Yuqing Yuan, Zhuolin Li, Jiachen Li, Jing Li, Xin Jia, Yifan He, Tian Zhu, Jiangyuan Sun, Yu Jiang, Wengting Zhang, Hui Wang, Cheng Ke, Zunfu Mol Cancer Review Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs. BioMed Central 2020-01-24 /pmc/articles/PMC6982393/ /pubmed/31980023 http://dx.doi.org/10.1186/s12943-020-1141-9 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Zhong, Xiaoming Zhang, Hangtian Zhu, Ying Liang, Yuqing Yuan, Zhuolin Li, Jiachen Li, Jing Li, Xin Jia, Yifan He, Tian Zhu, Jiangyuan Sun, Yu Jiang, Wengting Zhang, Hui Wang, Cheng Ke, Zunfu Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy |
title | Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy |
title_full | Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy |
title_fullStr | Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy |
title_full_unstemmed | Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy |
title_short | Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy |
title_sort | circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982393/ https://www.ncbi.nlm.nih.gov/pubmed/31980023 http://dx.doi.org/10.1186/s12943-020-1141-9 |
work_keys_str_mv | AT zhongxiaoming circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT zhanghangtian circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT zhuying circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT liangyuqing circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT yuanzhuolin circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT lijiachen circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT lijing circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT lixin circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT jiayifan circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT hetian circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT zhujiangyuan circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT sunyu circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT jiangwengting circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT zhanghui circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT wangcheng circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy AT kezunfu circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy |